Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CTSA | P10619 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17357035 | 0.82 | TSHR (0.53) | TSHRALDH1A1L3MBTL1POLBMEN1 | |
| SCHEMBL27969393 | 0.82 | TSHR (0.53) | TSHRALDH1A1L3MBTL1POLBMEN1 | |
| SCHEMBL1034487 | 0.81 | TSHR (0.52) | TSHRALDH1A1L3MBTL1POLBMEN1 | |
| SCHEMBL11538617 | 0.79 | TSHR (0.70) | TSHRALDH1A1L3MBTL1POLBMEN1 | |
| SCHEMBL4586530 | 0.79 | TSHR (0.50) | TSHRALDH1A1L3MBTL1POLBMEN1 | |
| SCHEMBL4586559 | 0.79 | TSHR (0.53) | TSHRALDH1A1POLBMEN1KMT2A | |
| SCHEMBL4586535 | 0.77 | TSHR (0.47) | TSHRALDH1A1L3MBTL1POLBMEN1 | |
| SCHEMBL7336647 | 0.77 | TSHR (0.51) | TSHRALDH1A1L3MBTL1POLBMEN1 | |
| SCHEMBL27497415 | 0.76 | TSHR (0.50) | TSHRALDH1A1L3MBTL1POLBMEN1 | |
| SCHEMBL9816599 | 0.76 | TSHR (0.46) | TSHRALDH1A1L3MBTL1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385988-A4 | SELECTIVE COVALENT-BINDING COMPOUNDS HAVING THERAPEUTIC DIAGNOSTIC AND ANALYTICAL APPLICATIONS | SEMOREX INC (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20040121405-A1 | Selective covalent-binding compounds having therapeutic diagnostic and analytical applications | SEMOREX INC. | 2004-06-24 | — | — | US | disclosed |
| EP-1385988-A2 | SELECTIVE COVALENT-BINDING COMPOUNDS HAVING THERAPEUTIC DIAGNOSTIC AND ANALYTICAL APPLICATIONS | Semorex Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002083708-A2 | SELECTIVE COVALENT-BINDING COMPOUNDS HAVING THERAPEUTIC DIAGNOSTIC AND ANALYTICAL APPLICATIONS | SEMOREX INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121405-A1 | Selective covalent-binding compounds having therapeutic diagnostic and analytical applications | CD2BP2, HAVCR2, EPCAM | TSHR 394/4885CTSA 1711/4885ACHE 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.